Skip to main content
. 2019 Mar 26;12(5):788–799. doi: 10.1016/j.tranon.2019.02.003

Figure 8.

Figure 8

(A) Bismuth serum concentrations in five groups of mice with BiZn dose of 0.14 mmol/kg. The plots show the levels of bismuth content in serum as means ± SEM over the full 6-hour time course. (B) Effect of high dose of BiZn treatment on organ histology change of mice. Mice received BiZn (0.58 mmol/kg) treatment for 5 days. Brains, hearts, kidneys, lungs, and livers were formalin-fixed, paraffin-embedded, and H&E-stained. Based on the figures, none of the organs appeared to show any evidence of brain, heart, kidney, lung, or liver damage. (C) Effect of BiZn on renal histology in cisplatin-treated SCID Beige mice. (C-a) Renal histological changes after 21 days of cisplatin administration (day 1: 7.5 mg/kg, day 2: 7.5/kg, and day 15: 15 kg/kg). (C-b) Renal histological changes with same condition of cisplatin combined with BiZn every 2 days. Photo showed protein cast, vacuolation, and desquamation of epithelial cells in the renal tubules after cisplatin administration. The injuries were attenuated by treatment of BiZn every 2-day injection. (D and E) Effect of pretreatment with BiZn on renal protection with or without cisplatin treatment on SCID Beige mice. In (D-a), mice were treated with BiZn for 3 weeks without cisplatin treatment. In (D-b and E), mice were pretreated orally with BiZn for 24 hours and just prior to cisplatin (15 mg/kg) injection. The mice were sacrificed on day 5. Blood BUN and creatinine levels were determined after the end point. Each value for BUN and creatinine represents the mean ± SEM (BUN, n = 6, cisplatin vs. control group, ***P < .001; n = 6 cisplatin vs. BiZn+cisplatin group, **P < .01) (creatinine, n = 4, cisplatin vs. control group, ***P < .001; n = 4 cisplatin vs. BiZn+cisplatin group, *P < .05). (F) Survival curve of cisplatin-treated SCID Beige mice with or without treatment of BiZn. Kaplan-Meier survival curve showed that the survival of mice of cisplatin group was significantly shorter than that of mice treated with BiZn+cisplatin (log-rank statistics: cisplatin vs. BiZn+cisplatin. ***P = .001).